Petryszyn P - Search Results

1

Petryszyn P, Chapelle N, Matysiak-Budnik T. Petryszyn P, et al. Dig Dis. 2020;38(4):280-285. doi: 10.1159/000506509. Epub 2020 Feb 17. Dig Dis. 2020. PMID: 32062657 Free article. Review.

2

A panel of stomach-specific biomarkers (GastroPanel®) for the diagnosis of atrophic gastritis: A prospective, multicenter study in a low gastric cancer incidence area.

Chapelle N, Petryszyn P, Blin J, Leroy M, Le Berre-Scoul C, Jirka I, Neunlist M, Moussata D, Lamarque D, Olivier R, Tougeron D, Mosnier JF, Matysiak-Budnik T. Chapelle N, et al. Among authors: petryszyn p. Helicobacter. 2020 Oct;25(5):e12727. doi: 10.1111/hel.12727. Epub 2020 Jul 23. Helicobacter. 2020. PMID: 32700438

3

C3435T Polymorphism of the ABCB1 Gene in Polish Patients with Inflammatory Bowel Disease: A Case-Control and Meta-Analysis Study.

Petryszyn P, Dudkowiak R, Gruca A, Jaźwińska-Tarnawska E, Ekk-Cierniakowski P, Poniewierka E, Wiela-Hojeńska A, Głowacka K. Petryszyn P, et al. Genes (Basel). 2021 Sep 15;12(9):1419. doi: 10.3390/genes12091419. Genes (Basel). 2021. PMID: 34573401 Free PMC article.

4

Stool patterns and symptoms of disordered anorectal function in patients with inflammatory bowel diseases.

Petryszyn PW, Paradowski L. Petryszyn PW, et al. Adv Clin Exp Med. 2018 Jun;27(6):813-818. doi: 10.17219/acem/68986. Adv Clin Exp Med. 2018. PMID: 29893516 Free article.

5

Economic implications of biological therapy for Crohn's disease.

Petryszyn PW, Paradowski L. Petryszyn PW, et al. Prz Gastroenterol. 2015;10(4):197-202. doi: 10.5114/pg.2015.55749. Epub 2015 Nov 23. Prz Gastroenterol. 2015. PMID: 26759625 Free PMC article. Review.

6

Infliximab, adalimumab, golimumab, vedolizumab and tofacitinib in moderate to severe ulcerative colitis: comparative cost-effectiveness study in Poland.

Petryszyn P, Ekk-Cierniakowski P, Zurakowski G. Petryszyn P, et al. Therap Adv Gastroenterol. 2020 Aug 25;13:1756284820941179. doi: 10.1177/1756284820941179. eCollection 2020. Therap Adv Gastroenterol. 2020. PMID: 32922513 Free PMC article.

7

Faecal calprotectin as a diagnostic marker of inflammatory bowel disease in patients with gastrointestinal symptoms: meta-analysis.

Petryszyn P, Staniak A, Wolosianska A, Ekk-Cierniakowski P. Petryszyn P, et al. Eur J Gastroenterol Hepatol. 2019 Nov;31(11):1306-1312. doi: 10.1097/MEG.0000000000001509. Eur J Gastroenterol Hepatol. 2019. PMID: 31464777

8

ECONOMIC ISSUES IN THERAPEUTIC DRUG MONITORING.

Petryszyn P, Wiela-Hojeńska A. Petryszyn P, et al. Acta Pol Pharm. 2016 May-Jun;73(3):599-604. Acta Pol Pharm. 2016. PMID: 27476276 Review.

9

Enhanced formation of advanced oxidation protein products in IBD.

Krzystek-Korpacka M, Neubauer K, Berdowska I, Boehm D, Zielinski B, Petryszyn P, Terlecki G, Paradowski L, Gamian A. Krzystek-Korpacka M, et al. Among authors: petryszyn p. Inflamm Bowel Dis. 2008 Jun;14(6):794-802. doi: 10.1002/ibd.20383. Inflamm Bowel Dis. 2008. PMID: 18213700

10

Costs in inflammatory bowel diseases.

Petryszyn PW, Witczak I. Petryszyn PW, et al. Prz Gastroenterol. 2016;11(1):6-13. doi: 10.5114/pg.2016.57883. Epub 2016 Feb 11. Prz Gastroenterol. 2016. PMID: 27110304 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

18 results

Search Page